3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
4
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
8
Recurrence
2
Neoplasm Metastasis
2
Breast Neoplasms
2
Thrombocytosis
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Breast Cancer With Intracranial Metastases
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hormone-Resistant Prostate Cancer
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Interventions
enzalutamide
2
cabazitaxel
1
Prednisone
1
Positron Emission Tomography Computed Tomography
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Prostate Cancer Metastatic
×
cabazitaxel
×
Clear all
NCT02379390
2019-06-21
PRIMCAB
Sanofi
Phase 2
Terminated
8 enrolled
8 charts